PRVA Stock Analysis: Privia Health | NASDAQ
Health Information Services | NASDAQ, USA | Market Cap: 2.983m USD | 12M Return: 22.2% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 28.6M
EPS Trend: 31.7%
Qual. Beats: -1
Rev. Trend: 96.6%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 5.3 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Privia Health Group (PRVA) is a US-based physician-enablement company that partners with physician practices, health plans, and health systems to support value-based care delivery. Founded in 2007 and headquartered in Arlington, Virginia, the company provides technology, population health tools, management services, and a single-TIN medical group structure that helps providers reduce administrative burden and negotiate more effectively with payers. It also operates an accountable care organization (ACO) and a broader provider network designed to improve care coordination and patient outcomes. The company went public on NASDAQ in April 2021 and is classified within the Health Care Services sub-industry, operating in a sector increasingly focused on shifting reimbursement away from fee-for-service toward risk-bearing, outcomes-based arrangements.
- Medical margin expansion drives adjusted EBITDA profitability
- New physician practice partnerships accelerate attributed member growth
- CMS value-based care regulations shape ACO shared savings revenue
| Net Income: 21.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA -0.35 > 1.0 |
| NWC/Revenue: 16.23% < 20% (prev 23.08%; Δ -6.84% < -1%) |
| CFO/TA 0.10 > 3% & CFO 138.0m > Net Income 21.8m |
| Net Debt (-410.5m) to EBITDA (56.4m): -7.28 < 3 |
| Current Ratio: 1.61 > 1.5 & < 3 |
| Outstanding Shares: last quarter (130.9m) vs 12m ago 2.45% < -2% |
| Gross Margin: 9.59% > 18% (prev 10.09%; Δ -0.51% > 0.5%) |
| Asset Turnover: 172.7% > 50% (prev 152.2%; Δ 20.53% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.26 (Total Current Assets 966.0m - Total Current Liabilities 601.3m) / Total Assets 1.42b |
| B: -0.11 (Retained Earnings -153.2m / Total Assets 1.42b) |
| C: 0.03 (EBIT TTM 45.1m / Avg Total Assets 1.30b) |
| D: 1.23 (Book Value of Equity 753.1m / Total Liabilities 612.0m) |
| Altman-Z'' = 2.86 = A |
| DSRI: 1.06 (Receivables 513.7m/388.7m, Revenue 2.25b/1.80b) |
| GMI: 1.05 (GM 10.09% / 9.59%) |
| AQI: 1.27 (AQ_t 0.31 / AQ_t-1 0.25) |
| SGI: 1.25 (Revenue 2.25b / 1.80b) |
| TATA: -0.08 (NI 21.8m - CFO 138.0m) / TA 1.42b) |
| Beneish M = -2.60 (Cap -4..+1) = A |
As of August 04, 2026, the stock is trading at USD 23.79 with a total of 642,940 shares traded. Over the past week, the price has changed by -3.57%, over one month by -12.50%, over three months by -1.86% and over the past year by +22.19%.
Current recommended Stop Loss: 22.00 (which is 7.5% or 2.1 ATR below the current price).
Privia Health has received a consensus analysts rating of 4.57. Therefore, it is recommended to buy PRVA.
- StrongBuy: 14
- Buy: 5
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 31.9 | 34% |
P/E Trailing = 139.2353
P/E Forward = 26.0417
P/S = 1.3277
P/B = 3.9608
Revenue TTM = 2.25b USD
EBIT TTM = 45.1m USD
EBITDA TTM = 56.4m USD
Long Term Debt = 6.91m USD (estimated: total debt 9.02m - short term 2.11m)
Short Term Debt = 2.11m USD (from shortTermDebt, last quarter)
Debt = 9.02m USD (from shortLongTermDebtTotal, last quarter) (leases 9.02m already included)
Net Debt = -410.5m USD (calculated: Debt 9.02m - CCE 419.5m)
Enterprise Value = 2.57b USD (2.98b + Debt 9.02m - CCE 419.5m)
Interest Coverage Ratio = unknown (Ebit TTM 45.1m / Interest Expense TTM 0.0)
EV/FCF = 18.81x (Enterprise Value 2.57b / FCF TTM 136.8m)
FCF Yield = 5.32% (FCF TTM 136.8m / Enterprise Value 2.57b)
FCF Margin = 6.09% (FCF TTM 136.8m / Revenue TTM 2.25b)
Net Margin = 0.97% (Net Income TTM 21.8m / Revenue TTM 2.25b)
Gross Margin = 9.59% ((Revenue TTM 2.25b - Cost of Revenue TTM 2.03b) / Revenue TTM)
Gross Margin QoQ = 9.44% (prev 9.18%)
Tobins Q-Ratio = 1.81 (Enterprise Value 2.57b / Total Assets 1.42b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 9.02m)
Taxrate = 39.27% (17.7m / 45.1m)
NOPAT = 27.4m (EBIT 45.1m * (1 - 39.27%))
Current Ratio = 1.61 (Total Current Assets 966.0m / Total Current Liabilities 601.3m)
Debt / Equity = 0.01 (Debt 9.02m / totalStockholderEquity, last quarter 753.1m)
Debt / EBITDA = -7.28 (Net Debt -410.5m / EBITDA 56.4m)
Debt / FCF = -3.00 (Net Debt -410.5m / FCF TTM 136.8m)
Total Stockholder Equity = 720.6m (last 4 quarters mean from totalStockholderEquity)
RoA = 1.67% (Net Income 21.8m / Total Assets 1.42b)
RoE = 3.02% (Net Income TTM 21.8m / Total Stockholder Equity 720.6m)
RoCE = 6.20% (EBIT 45.1m / Capital Employed (Equity 720.6m + L.T.Debt 6.91m))
RoIC = 3.88% (NOPAT 27.4m / Invested Capital 706.4m)
WACC = 7.88% (E(2.98b)/V(2.99b) * Re(7.90%) + D(9.02m)/V(2.99b) * Rd(0.0%) * (1-Tc(0.39)))
Discount Rate = 7.90% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 98.07 | Cagr: 2.12%
[DCF] Terminal Value 77.97% ; FCFF base≈129.4m ; Y1≈148.3m ; Y5≈218.3m
[DCF] Fair Price = 29.33 (EV 3.29b - Net Debt -410.5m = Equity 3.70b / Shares 126.0m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 31.66 | EPS CAGR: 5.27% | SUE: -2.01 | # QB: -1
Revenue Correlation: 96.64 | Revenue CAGR: 13.88% | SUE: 0.25 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.24 | Chg30d=-1.09% | Revisions=-42% | Analysts=11
EPS next Quarter (2026-09-30): EPS=0.26 | Chg30d=-0.69% | Revisions=-42% | Analysts=11
EPS current Year (2026-12-31): EPS=0.95 | Chg30d=-0.12% | Revisions=-50% | GrowthEPS=-3.9% | GrowthRev=+14.2%
EPS next Year (2027-12-31): EPS=1.10 | Chg30d=+0.01% | Revisions=-31% | GrowthEPS=+15.4% | GrowthRev=+10.0%
[Analyst] Revisions Ratio: -50% (up=9, down=30)